Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IONS vs SYRE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SYRE Captures Overall Composite Edge (44.4 HOLD vs 63.9 BUY), While IONS Leads 4–2 on Growth & Valuation Pillars

SYRE Overall Winner 6-Pillar Tally: IONS 4 – 2 SYRE Matrix Metrics: IONS 4 – 6 SYRE

As of Nov 16, 2026, Spyre Therapeutics, Inc. (SYRE) captures the overall head-to-head institutional edge over Ionis Pharmaceuticals, Inc. (IONS) on higher Unified Composite conviction (44.4/100 HOLD vs. 63.9/100 BUY) after splitting the core matrix 6–4 (led by Profitability & Quality, Options & Positioning), while IONS wins 4–2 across the 6-pillar growth and valuation breakdown. IONS trades at $28.57 (90.9x Forward P/E, -58.8% operating margin) versus SYRE at $99.97 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. SYRE 44.4/100 HOLD), SYRE captures the overall institutional head-to-head verdict (6–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -58.8% operating margin) and revenue trajectory (+0.0% vs. +54.9% YoY).
  • Technical & Structure Timing Caution: IONS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7); meanwhile SYRE trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 53.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IONS vs SYRE
IONS NASDAQ
Ionis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.57
-1.7% 1D
Market Cap $4.7B
TTM Revenue $960M
Forward P/E 90.9x
Beta / 30D Vol 0.18β · 86% Vol
Unified Composite Score
63.9 / 100 BUY
Tech 60.0 Fund 63.0 Flow 73.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.3%), weak momentum, RSI 24
RSI-14: 23.7 · SMA20: $38.46 · SMA50: $43.07
SYRE NASDAQ Head-to-Head Winner
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.75β · 59% Vol
Unified Composite Score
44.4 / 100 HOLD
Tech 31.0 Fund 33.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 53.5 · SMA20: $98.78 · SMA50: $91.70

6-Pillar Scorecard Institutional Category Breakdown (IONS 4 – 2 SYRE)

Columns: Metric · IONS · SYRE
1. Valuation Multiples IONS
Forward P/E 90.9x N/M
Trailing P/E 90.9x N/M
PEG Ratio N/M N/M
EV / Revenue 6.2x N/M
2. Growth & Scale IONS
Revenue Growth (YoY) +54.9% +0.0%
Earnings Growth (YoY) -43.7% -99.7%
TTM Revenue (USD) $960M N/A
Market Cap $4.7B $9.8B
3. Profitability & Quality SYRE
Gross Margin 3.0% N/A
Operating Margin -58.8% 0.0%
Net Profit Margin -56.9% 0.0%
Return on Equity (ROE) -108.0% -35.0%
4. Balance Sheet & Cash Flow IONS
Cash Generation (TTM) -$623M N/A
Cash Flow Margin -64.9% N/A
Net Cash / Leverage $1.33B Net Debt (4.14x D/E) $10.06 Book/Sh · -35.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SYRE
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 59.9% (17th %ile) 87.9% (10th %ile)
Put/Call OI Skew 1.81x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat IONS
OpEx & R&D Intensity 61.8% of Rev ($593M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IONS (4) vs SYRE (6)
Institutional Metric IONS SYRE Criterion Row Edge
Market Capitalization
Scale
$4.7B $9.8B Larger Scale SYRE
Trailing P/E Ratio
Valuation
90.9x N/M Lower Multiple IONS
Forward P/E Ratio
Valuation
90.9x N/M Lower Multiple IONS
Revenue Growth (YoY)
Growth
+54.9% +0.0% Higher Growth IONS
Operating Margin (TTM)
Profitability
-58.8% 0.0% Higher Margin SYRE
Net Profit Margin
Profitability
-56.9% 0.0% Higher Margin SYRE
Return on Equity (ROE)
Capital Efficiency
-108.0% -35.0% Higher ROE SYRE
52-Week Range Position
Momentum
2% ($27–$87) 88% ($22–$111) Stronger Trend SYRE
Beta / 30D Volatility
Risk Regime
0.18β · 86% Vol 1.75β · 59% Vol Lower Realized Risk SYRE
Unified Institutional Score
Composite Signal
63.9 / 100 (BUY) 44.4 / 100 (HOLD) Higher Composite IONS
Trailing 12M Revenue (USD)
Operating Scale
$960M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
3.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.2x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$623M ($1.33B Net Debt (4.14x D/E)) N/A ($10.06 Book/Sh · -35.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SYRE +58.59 pp
IONS: -33.48% · SYRE: +25.11%
3M Horizon SYRE +44.8 pp
IONS: -52.09% · SYRE: -7.29%
6M Horizon SYRE +103.25 pp
IONS: -60.61% · SYRE: +42.64%
1Y Horizon SYRE +400.84 pp
IONS: -59.1% · SYRE: +341.74%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IONS vs SYRE. Trailing 12-month operating profitability (IONS -58.8% vs SYRE 0.0%) and valuation multiples (IONS 90.9x vs SYRE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

IONS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$960M
Gross Margin3.0%
Op. Margin-58.8%
ROE / Fwd P/E-108.0% · 90.9x
SYRE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-35.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IONS BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 59.9%
IV Percentile 17th %ile
Put/Call OI Skew 1.81x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact IONS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SYRE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SYRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IONS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.7B market capitalization and -58.8% operating margin.
OpEx & R&D Reinvestment 61.8% of Rev ($593M)
90D Engineering Disclosures 0 Published
SYRE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.8B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IONS vs SYRE Key Questions & Quantitative Answers

As of Nov 16, 2026, Spyre Therapeutics, Inc. (SYRE) captures the overall head-to-head institutional edge over Ionis Pharmaceuticals, Inc. (IONS) on higher Unified Composite conviction (44.4/100 HOLD vs. 63.9/100 BUY) after splitting the core matrix 6–4 (led by Profitability & Quality, Options & Positioning), while IONS wins 4–2 across the 6-pillar growth and valuation breakdown. IONS trades at $28.57 (90.9x Forward P/E, -58.8% operating margin) versus SYRE at $99.97 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. SYRE 44.4/100 HOLD), SYRE captures the overall institutional head-to-head verdict (6–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -58.8% operating margin) and revenue trajectory (+0.0% vs. +54.9% YoY). Technical & Structure Timing Caution: IONS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7); meanwhile SYRE trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 53.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IONS leads the Growth & Scale pillar: IONS posts +54.9% YoY revenue growth and -43.7% YoY earnings growth on $960M TTM revenue (3.0% gross margin, -58.8% operating margin), compared with SYRE at +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, IONS generates $960M in USD-normalized revenue versus N/A for SYRE. In operating R&D and SG&A reinvestment, IONS deploys 61.8% of Rev ($593M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SYRE.

IONS screens cheaper on headline valuation multiples. IONS trades at 90.9x Forward P/E, 90.9x Trailing P/E, N/M PEG, and 6.2x EV/Revenue (-64.9% FCF margin), whereas SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IONS (-108.0% ROE) versus SYRE (-35.0% ROE) capital efficiency.

In options market volatility and institutional positioning, IONS carries 59.9% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.81x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.18β · 86% Vol realized risk). By comparison, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.75β · 59% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.